3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
3
Classical hematology
1
Conditions
Hematologic Neoplasms
1
Febrile Neutropenia
1
Interventions
Cyclophosphamide
93
fludarabine phosphate
86
Busulfan
63
Cyclosporine
57
Peripheral Blood Stem Cell Transplantation
54
Mycophenolic Acid
54
Whole-Body Irradiation
53
Epoetin Alfa
53
Antilymphocyte Serum
43
fludarabine
42
Filgrastim
41
Cytarabine
41
Tacrolimus
39
Melphalan
38
Darbepoetin alfa
38
Methotrexate
34
Radiotherapy
32
Cord Blood Stem Cell Transplantation
28
Granulocyte Colony-Stimulating Factor
23
Methylprednisolone
21
Etoposide
21
apixaban
18
eltrombopag
16
Thiotepa
16
Dalteparin
16
ferric carboxymaltose
14
Daunorubicin
14
Azacitidine
14
Alemtuzumab
14
thymoglobulin
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
ceftolozane, tazobactam drug combination
×
Classical hematology
×
Clear all
NCT05061654
2023-08-14
CEF-10
Hamad Medical Corporation
Phase 4
Withdrawn